DZ3320A1 - Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine - Google Patents

Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine

Info

Publication number
DZ3320A1
DZ3320A1 DZ013320A DZ013320A DZ3320A1 DZ 3320 A1 DZ3320 A1 DZ 3320A1 DZ 013320 A DZ013320 A DZ 013320A DZ 013320 A DZ013320 A DZ 013320A DZ 3320 A1 DZ3320 A1 DZ 3320A1
Authority
DZ
Algeria
Prior art keywords
eletriptane
sulphobutylether
migraine
cyclodextrin
complex
Prior art date
Application number
DZ013320A
Other languages
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ3320A1 publication Critical patent/DZ3320A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DZ013320A 1999-06-29 2000-06-02 Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine DZ3320A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (fr) 1999-06-29 2000-06-02 Complexe pharmaceutique

Publications (1)

Publication Number Publication Date
DZ3320A1 true DZ3320A1 (fr) 2001-01-04

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013320A DZ3320A1 (fr) 1999-06-29 2000-06-02 Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine

Country Status (44)

Country Link
US (2) US6713461B1 (fr)
EP (1) EP1189640B1 (fr)
JP (2) JP4454900B2 (fr)
KR (1) KR20020015067A (fr)
CN (1) CN1198654C (fr)
AP (1) AP2001002369A0 (fr)
AR (1) AR033337A1 (fr)
AT (1) ATE290884T1 (fr)
AU (1) AU770169B2 (fr)
BG (1) BG106151A (fr)
BR (1) BR0011845A (fr)
CA (1) CA2376847C (fr)
CO (1) CO5170494A1 (fr)
CZ (1) CZ20014572A3 (fr)
DE (1) DE60018744T2 (fr)
DZ (1) DZ3320A1 (fr)
EA (1) EA003908B1 (fr)
EC (1) ECSP003551A (fr)
EE (1) EE200100697A (fr)
ES (1) ES2235879T3 (fr)
GB (1) GB9915231D0 (fr)
GE (1) GEP20043377B (fr)
GT (1) GT200000102A (fr)
HR (1) HRP20010951A2 (fr)
HU (1) HUP0201629A3 (fr)
IL (1) IL146341A0 (fr)
IS (1) IS6163A (fr)
MA (1) MA26801A1 (fr)
MX (1) MXPA01013274A (fr)
NO (1) NO20016430L (fr)
NZ (1) NZ515235A (fr)
OA (1) OA11964A (fr)
PA (1) PA8496801A1 (fr)
PE (1) PE20010346A1 (fr)
PL (1) PL352902A1 (fr)
SK (1) SK18932001A3 (fr)
SV (1) SV2002000112A (fr)
TN (1) TNSN00142A1 (fr)
TR (1) TR200103827T2 (fr)
UA (1) UA66932C2 (fr)
UY (1) UY26224A1 (fr)
WO (1) WO2001000243A1 (fr)
YU (1) YU87501A (fr)
ZA (1) ZA200110454B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
NZ537995A (en) * 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (fr) * 2016-01-15 2017-07-20 Cadila Healthcare Limited Composition intranasale comprenant des agonistes de récepteur 5ht1b/1d
WO2019143925A1 (fr) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Compositions liquides de rizatriptan

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU225055B1 (en) 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
RU2143896C1 (ru) 1993-03-05 2000-01-10 Хексаль Аг Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
EP0999841B1 (fr) 1997-07-03 2001-10-17 Pfizer Limited Compositions pharmaceutiques contenant l'hemisulfate d'eletriptane et de la cafeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
GB9915231D0 (en) 1999-09-01
EP1189640B1 (fr) 2005-03-16
WO2001000243A1 (fr) 2001-01-04
PE20010346A1 (es) 2001-03-26
BR0011845A (pt) 2002-03-05
NO20016430L (no) 2002-02-26
HUP0201629A3 (en) 2003-11-28
HRP20010951A2 (en) 2005-04-30
AU4774100A (en) 2001-01-31
CA2376847A1 (fr) 2001-01-04
PL352902A1 (en) 2003-09-22
CN1359303A (zh) 2002-07-17
ATE290884T1 (de) 2005-04-15
US20040186076A1 (en) 2004-09-23
US6713461B1 (en) 2004-03-30
CO5170494A1 (es) 2002-06-27
NZ515235A (en) 2003-08-29
IL146341A0 (en) 2002-07-25
OA11964A (en) 2006-04-17
JP4454900B2 (ja) 2010-04-21
ZA200110454B (en) 2002-12-20
DE60018744D1 (de) 2005-04-21
UA66932C2 (en) 2004-06-15
EA200101106A1 (ru) 2002-06-27
NO20016430D0 (no) 2001-12-28
ES2235879T3 (es) 2005-07-16
EE200100697A (et) 2003-02-17
SV2002000112A (es) 2002-02-05
MXPA01013274A (es) 2002-06-04
HUP0201629A2 (hu) 2003-03-28
SK18932001A3 (sk) 2002-09-10
YU87501A (sh) 2004-05-12
EP1189640A1 (fr) 2002-03-27
TNSN00142A1 (fr) 2005-11-10
JP2006257091A (ja) 2006-09-28
TR200103827T2 (tr) 2002-05-21
AU770169B2 (en) 2004-02-12
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
GT200000102A (es) 2001-12-14
PA8496801A1 (es) 2002-02-21
GEP20043377B (en) 2004-04-13
CN1198654C (zh) 2005-04-27
DE60018744T2 (de) 2006-05-18
MA26801A1 (fr) 2004-12-20
KR20020015067A (ko) 2002-02-27
BG106151A (en) 2002-05-31
AR033337A1 (es) 2003-12-17
JP2003503364A (ja) 2003-01-28
ECSP003551A (es) 2002-01-25
AP2001002369A0 (en) 2001-12-31
CA2376847C (fr) 2007-09-25
UY26224A1 (es) 2001-01-31
CZ20014572A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
FR2754713B1 (fr) Utilisation de complexes pour la preparation de compositions pour le traitement des peaux sensibles, procede de preparation et compositions hypoallergeniques
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
EP1175218A4 (fr) Therapie oculaire pour la keratoconjonctivite seche basee sur l'application locale d'androgenes ou de tgf-beta
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1300963A4 (fr) Appareil de traitement d'echos
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
EP1575577A4 (fr) Composition pour la prevention et le traitement de l'inflammation de l'oreille
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
EP1553920A4 (fr) Preparation topique pour la prevention et le traitement de l'acne
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
MA24332A1 (fr) Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau
FR2857597B1 (fr) Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
EP1161255A4 (fr) Procedes et compositions pour le traitement de la dyserection
EP1448193A4 (fr) Composes therapeutiques pour le traitement d'etats dyslipidemiques
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
FR2758465B1 (fr) Composition pour le traitement de l'amiante
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
EP1572129A4 (fr) Derives d'amidine pour le traitement des amyloses
MA25852A1 (fr) Methode pour le traitement de l'inflammation.